Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Plerixafor octahydrochloride (JM3100 octahydrochloride) 是一种选择性的CXCR4拮抗剂,IC50为 44 nM。Plerixafor 是一种具有造血干细胞动员活性的双环霉素。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 166 | 现货 | ||
5 mg | ¥ 335 | 现货 | ||
10 mg | ¥ 517 | 现货 | ||
25 mg | ¥ 928 | 现货 | ||
50 mg | ¥ 1,610 | 现货 | ||
100 mg | ¥ 2,690 | 现货 | ||
200 mg | ¥ 3,960 | 现货 | ||
500 mg | ¥ 6,260 | 现货 |
产品描述 | Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. |
靶点活性 | CXCR4:44 nM, CXCL12:5.7 nM |
体外活性 | AMD 3100 can inhibit the replication of low-passage clinical HIV-1 isolates (K31, D370, K6/-2, HEM, and JRCSF) in primary T4 lymphocytes (EC50s: 0.16-1.5 ng/ml; EC90s: 0.36-4.7 ng/ml). In primary monocytes, AMD 3100 was active against HIV-1 (K31 and SF-162) at EC50s of 0.28-7.2 ng/mL and EC90s of 0.68-12 ng/mL. |
体内活性 | Serum drug levels in rabbits given AMD 3100 (10 mg/kg) by the subcutaneous route were determined by a bioassay based on the EC50 of the compound required to inhibit HIV-1 cytopathicity in MT-4 cells. |
细胞实验 | Plerixafor is dissolved in DMSO and then diluted with appropriate medium[2]. U87 mg cells are seeded in 96-well plates at the density of 6×103 cells in 200 μL/well and treated with CXCL12, Plerixafor or with peptide R, as described in the previous "Treatments" section. MTT (5 μg/mL) is added at each time point (24, 48, 72 h) during the final 2 h of treatment. After removing cell medium, 100 μL DMSO are added and optical densities measured at 595 nm with a LT-4000MS Microplate Reader. Measurements are made in triplicates from three independent experiments[2]. |
别名 | 盐酸普乐沙福, JM3100 octahydrochloride, Plerixafor 8HCl (AMD3100 8HCl), Plerixafor 8HCl, SID791 octahydrochloride, AMD 3100 octahydrochloride, JM 3100 8HCl |
分子量 | 794.46 |
分子式 | C28H62Cl8N8 |
CAS No. | 155148-31-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Insoluble
H2O: 119.17 mg/mL (150 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 1.2587 mL | 6.2936 mL | 12.5872 mL | 31.4679 mL |
5 mM | 0.2517 mL | 1.2587 mL | 2.5174 mL | 6.2936 mL | |
10 mM | 0.1259 mL | 0.6294 mL | 1.2587 mL | 3.1468 mL | |
20 mM | 0.0629 mL | 0.3147 mL | 0.6294 mL | 1.5734 mL | |
50 mM | 0.0252 mL | 0.1259 mL | 0.2517 mL | 0.6294 mL | |
100 mM | 0.0126 mL | 0.0629 mL | 0.1259 mL | 0.3147 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Plerixafor octahydrochloride 155148-31-5 Autophagy GPCR/G Protein Immunology/Inflammation Microbiology/Virology Proteases/Proteasome HIV Protease Virus Protease CXCR AMD 3100 SID 791 SID-791 JM-3100 Octahydrochloride AMD-3100 Octahydrochloride SID-791 Octahydrochloride JM3100 Octahydrochloride AMD-3100 Plerixafor Octahydrochloride AMD3100 8HCl 盐酸普乐沙福 JM3100 octahydrochloride AMD3100 SID791 HIV CXC chemokine receptors SID 791 Octahydrochloride AMD3100 Octahydrochloride Plerixafor 8HCl (AMD3100 8HCl) AMD3100 octahydrochloride Human immunodeficiency virus inhibit JM 3100 Plerixafor 8HCl SID791 octahydrochloride Inhibitor JM-3100 AMD 3100 Octahydrochloride JM 3100 Octahydrochloride Plerixafor SID791 Octahydrochloride AMD 3100 octahydrochloride JM 3100 8HCl JM3100 inhibitor